



SMS Lifesciences India Limited

Registered & Corporate Office :

Plot No. 19-III, Road No. 71,
Opp. Bharatiya Vidya Bhavan Public School,
Jubilee Hills, Hyderabad - 500 096, Telangana, INDIA.
Tel : +91-040-6628 8888, Fax : +91-40-2355 1401
CIN : L74930TG2006PLC050223
Email : info@smslife.in, Website : www.smslife.in

August 13, 2021

To

BSE Limited,

Listing Department, P J Towers,
Dalal Street,
Mumbai – 400 001.

Scrip code: 540679

Through: BSE Listing Center

National Stock Exchange of India Limited,

Listing Department, "Exchange Plaza",
Bandra-Kurla Complex, Bandra (E),
Mumbai - 400 051.

Trading Symbol: SMSLIFE

Through: NEAPS

SUB: OUTCOME OF THE BOARD MEETING [financial results of Q1-F22]

Ref: Regulation 33 read with sub-para 4 & 12 of Para "A" of Part "A" of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

With reference to the above cited subject, we would like to inform you that the Board of Directors of the Company at their Meeting held on August 13, 2021, have *inter-alia* considered and approved the un-audited [Standalone and Consolidated] financial results for the quarter ended June 30, 2021, as recommended by the Audit Committee.

In this regard, we are enclosing herewith a copy of un-audited [Standalone and Consolidated] financial results for the quarter ended June 30, 2021 along with the Limited Review Reports received from the Statutory Auditors of the Company on the said results.

The meeting of the Board commenced at **4.00 pm** and concluded at **5.00 pm**.

For SMS Lifesciences India Limited

Trupti Ranjan Mohanty

Company Secretary



[Enclosed: Quarterly results along with Limited Review Reports]

SMS LIFESCIENCES INDIA LIMITED


(CIN: L74930TG2006PLC050223)

Regd. Office: Plot No.19-III, Opp. BVBP School, Road No.71, Jubilee Hills, Hyderabad - 500 096

Tel:+91-40-6628 8888, Fax:91-40-2355 1401, Email: info@smslife.in

Standalone Statement of Unaudited Financial Results for the Quarter Ended 30th June, 2021

S.No	Particulars	Quarter Ended			Year ended
		30.06.2021	31.03.2021	30.06.2020	31.03.2021
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	Revenue From Operations	7,322.46	7,952.31	5,477.76	26,025.55
2	Other Income	4.38	116.80	7.75	133.28
3	Total Revenue	7,326.84	8,069.11	5,485.51	26,158.83
4	Expenses				
	(a) Cost of Materials Consumed	4,054.23	4,512.24	2,540.82	13,775.91
	(b) Changes in Inventories	262.68	(274.44)	669.22	190.08
	(c) Manufacturing Expenses	1,239.05	1,412.12	758.64	4,665.83
	(d) Employee Benefits Expense	736.68	750.15	528.55	2,711.04
	(e) Finance Costs	106.85	97.45	118.21	450.02
	(f) Depreciation and Amortization Expense	196.66	181.49	178.57	721.33
	(g) Other Expenses	319.83	797.73	332.87	1,709.18
	Total Expenses - (a to g)	6,915.98	7,476.74	5,126.88	24,223.39
5	Profit Before Exceptional and Extraordinary Items and Tax (3-4)	410.86	592.37	358.63	1,935.44
6	Exceptional items	-	-	-	-
7	Profit Before Extraordinary Items and Tax (5-6)	410.86	592.37	358.63	1,935.44
8	Extraordinary Items	-	-	-	-
9	Profit Before Tax (7-8)	410.86	592.37	358.63	1,935.44
10	Tax Expenses				
	(1) Relating to Current Year	122.00	125.00	100.00	525.00
	(2) Relating to Earlier Year	-	(22.32)	-	(22.31)
	(3) Deferred Tax	(0.95)	94.32	7.21	115.92
		121.05	197.00	107.21	618.61
11	Net Profit / (Loss) for the Period (9-10)	289.81	395.37	251.42	1,316.83
	Other Comprehensive Income / (Loss)				
	Items that will not be reclassified to Profit & Loss				
12	Remeasurement Gain / (Loss) of the defined benefit plans	(4.38)	8.09	(6.81)	(12.35)
13	Income Tax effect on the above	(0.99)	2.36	(1.98)	(3.60)
14	Other Comprehensive Income / (Loss) after Tax for the period / Year (12-13)	(3.39)	5.73	(4.83)	(8.75)
15	Total Comprehensive Income for the period / Year (11+14)	286.42	401.10	246.59	1,308.08
16	Earnings Per Equity Share of Rs.10/- each Basic / Diluted (not annualised)	9.59	13.08	8.32	43.56
	Paid-up equity share capital (Face Value of Rs.10/- each)	302.33	302.33	302.33	302.33
17	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year				12,331.32



Notes:

- 1 The above standalone Financial Results have been reviewed and recommended by the Audit Committee on 13th August, 2021 and have been approved by the Board of Directors at its meeting held on 13th August, 2021.
- 2 The figures for the quarter ended 31st March 2021 are the balancing figures between audited figures in respect of full financial year upto 31st March 2021 and the unaudited published year to date figures upto 31st December 2020. Figures pertaining to previous Quarter under the head other expenses are not comparable due to writeoff of un realised debts during that Quarter
- 3 The standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act,2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations,2015.
- 4 The Company has not experienced any significant impact on its operations, supply chain and recoverability of carrying amounts of financial and non-financial assets due to COVID 19 pandemic. As the pandemic continues to evolve, the company will continue to closely monitor for any material changes to future economic conditions.
- 5 The Company is engaged in manufacturing of Active Pharmaceutical Ingredients and their intermediates and the same constitutes a single reportable business segment as per Ind AS108.
- 6 Figures for the previous period have been reclassified/ regrouped wherever necessary to conform to current period's classification.

Place: Hyderabad
Date : 13-08-2021



For SMS Lifesciences India


TVVSN Murthy
Managing Director
DIN: 00465198

Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended

**Review Report to
The Board of Directors
SMS Lifesciences India Limited**

We have reviewed the accompanying statement of unaudited standalone financial results of **SMS Lifesciences India Limited** ("the Company"), for the quarter ended 30th June 2021 ("the statement"), attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (the "Listing Regulations").

This statement which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 (Ind AS 34) "Interim Financial Reporting" prescribed under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to express conclusion on the Statements based on our review.


We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by Independent Auditor of Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statements is free of material misstatement. A review of the interim financial information consists of making inquires primarily of company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.


Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ("Ind AS") specified under Section 133 of Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad
Date: 13-08-2021

UDIN: 21026548AAAAIM6545

For Rambabu & Co.,
Chartered Accountants
Reg. No.0029765


GVL Prasad
Partner
M. No. 026548



SMS LIFESCIENCES INDIA LIMITED

(CIN: L74930TG2006PLC050223)


Regd. Office: Plot No.19-III, Opp. BVBP School, Road No.71, Jubilee Hills, Hyderabad - 500 096

Tel:+91-40-6628 8888, Fax:91-40-2355 1401, Email: info@smslife.in

Consolidated Statement of Unaudited Financial Results for the Quarter Ended 30th June, 2021

(Rs. In Lakhs)

S.No	Particulars	Quarter Ended			Year ended
		30.06.2021	31.03.2021	30.06.2020	31.03.2021
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	Revenue From Operations	7,627.00	8,251.38	5,474.90	26,559.18
2	Other Income	6.92	127.59	30.29	178.10
3	Total Revenue	7,633.92	8,378.97	5,505.19	26,737.28
4	Expenses				
	(a) Cost of Materials Consumed	3,957.91	4,508.25	2,459.73	13,516.65
	(b) Changes in Inventories	249.76	(322.01)	619.43	187.20
	(c) Manufacturing Expenses	1,382.71	1,555.05	807.32	5,020.67
	(d) Employee Benefits Expense	881.29	859.88	606.26	3,065.81
	(e) Finance Costs	111.87	98.80	118.70	452.93
	(f) Depreciation and Amortization Expense	212.68	197.45	194.76	786.16
	(g) Other Expenses	334.76	807.37	342.62	1,751.11
	Total Expenses - (a to g)	7,130.98	7,704.79	5,148.82	24,780.53
5	Profit Before Exceptional and Extraordinary Items and Tax (3-4)	502.94	674.18	356.37	1,956.75
6	Exceptional items	-	-	-	-
7	Profit Before Extraordinary Items and Tax (5-6)	502.94	674.18	356.37	1,956.75
8	Extraordinary Items	-	-	-	-
9	Profit Before Tax (7-8)	502.94	674.18	356.37	1,956.75
10	Tax Expenses				
	(1) Current Tax	142.00	115.50	101.00	526.50
	(2) Relating to Earlier Year	-	(38.93)	-	(38.93)
	(3) Deferred Tax	(1.83)	92.25	7.11	113.52
		140.17	168.82	108.11	601.09
11	Net Profit / (Loss) for the Period (9-10)	362.77	505.36	248.26	1,355.66
	Other Comprehensive Income/(Loss) (OCI):				
12	(A) Items that will not be reclassified to statement of Profit & Loss Remeasurement Gain / (Loss) of the defined benefit plans	(3.85)	8.80	(6.44)	(10.39)
13	Income Tax effect on the above	(0.84)	2.56	(1.88)	(3.05)
14	Other Comprehensive Income/(Loss) after tax for the Period / Year (12-13)	(3.01)	6.24	(4.56)	(7.34)
15	Total comprehensive Income for the period/year (14+14)	359.76	511.60	243.70	1,348.32
16	Earnings Per Equity Share of Rs.10/- each Basic / Diluted (not annualised)	12.00	16.72	8.21	44.84
17	Paid-up equity share capital (Face Value of Rs.10/- each)	302.33	302.33	302.33	302.33
18	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year				12,619.29



Notes:

- 1 The above consolidated Financial Results have been reviewed and recommended by the Audit Committee on 13th August, 2021 and have been approved by the Board of Directors at its meeting held on 13th August, 2021.
- 2 The figures for the quarter ended 31st March 2021 are the balancing figures between audited figures in respect of full financial year upto 31st March 2021 and the unaudited published year to date figures upto 31st December 2020. Figures pertaining to previous Quarter under the head other expenses are not comparable due to writeoff of un realised debts during that Quarter
- 3 The consolidated financial results of the Company have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
- 4 The Consolidated financial results include the financial results of Mahi Drugs Private Limited a wholly owned subsidiary and are prepared by applying Ind AS 110- "Consolidated Financial Statements".
- 5 The group has not experienced any significant impact on its operations, supply chain and recoverability of carrying amounts of financial and non-financial assets due to COVID 19 pandemic. As the pandemic continues to evolve, the company will continue to closely monitor for any material changes to future economic conditions.
- 6 The Group is engaged in manufacturing Active Pharmaceutical Ingredients and their intermediates and the same constitutes a single reportable business segment as per Ind AS108.
- 7 Figures for the previous period have been reclassified / regrouped wherever necessary to conform to current period's classification.

Place: Hyderabad
Date : 13-08-2021



For SMS Lifesciences India Limited

A blue handwritten signature consisting of a stylized 'L' shape with a dot at the top right.

TVVSN Murthy
Managing Director
DIN: 00465198

Independent Auditor's Review Report on review of Interim Consolidated Financial Results

To the Board of Directors of
SMS Lifesciences India Limited

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial results of **SMS Lifesciences India Limited** ("the Parent") and its subsidiary (the Parent and its subsidiary together referred to as "the Group") for the quarter ended 30th June, 2021 (the "statement"), being submitted by the parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

2. This statement is the responsibility of the Parent's Management and has been approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting (Ind AS 34)", prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim Financial information performed by the Independent Auditor of the Entity*, issued by Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the result of the following entities

- a. SMS Lifesciences India Limited
- b. M/s. Mahi Drugs Private Limited (wholly owned subsidiary)



5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.


6. The consolidated unaudited financial results includes the interim financial statements/ financial information of above subsidiary, whose interim financial statements / financial information reflect total revenue of Rs. 644.89 lakhs, total net profit after tax of Rs. 95.86 lakhs and total comprehensive income of Rs. 96.24 lakhs for the Quarter ended 30 June, 2021, as considered in the Statement. According to the information and explanations given to us by the Management, the interim financial statements / financial information is not material to the Group. Our conclusion on the Statement is not modified in respect of our reliance on the interim financial statements / financial information certified by the Management.

Place: Hyderabad

Date: 13-08-2021

UDIN: 21026548AAAAIL2117

For Rambabu & Co.,
Chartered Accountants
Reg. No.0029768


GVL Prasad

Partner

M. No. 026548

